AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon–Small-Cell Lung Cancer With <i>EGFR</i> Exon 19 Deletion or L858R Mutations

Lü, Shun; Dong, Xiaorong; Jian, Hong; Chen, Jianhua; Chen, Gongyan; Sun, Yuping; Ji, Yinghua; Wang, Ziping; Shi, Jianhua; Lu, Junguo; Chen, Shaoshui; Lv, Dongqing; Zhang, Guojun; Liu, Chunling; Li, Juan; Yu, Xinmin; Lin, Zhong; Yu, Zhuang; Wang, Zhehai; Cui, Jiuwei; Xu, Xingxiang; Fang, Jian; Feng, Jifeng; Xu, Zhixiang; Ma, Rui; Hu, Jie; Yang, Nong; Zhou, Xiangdong; Wu, Xiaohong; Hu, Chengping; Zhang, Zhihong; Lü, You; Hu, Yanping; Jiang, Liyan; Wang, Qiming; Guo, Renhua; Zhou, Jianying; Li, Baolan; Hu, Chunhong; Tong, Wan-cheng; Zhang, Helong; Ma, Lin; Chen, Yuan; Jie, Zhijun; Yao, Yu; Zhang, Longzhen; Jie, Weng; Li, Weidong; Xiong, Jianping; Ye, Xianwei; Duan, Jianchun; Yang, Haihua; Sun, Meili; Sun, Changan; Wei, Hongying; Li, Chuan; M. Ali, Siraj; A. Miller, Vincent; Wu, Qiong

doi:10.1200/jco.21.02641

Public

AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon–Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations

Published in Journal of Clinical Oncology • May 17, 2022

Authors:

Shun Lü

Xiaorong Dong

Hong Jian

Abstract

PURPOSE Aumolertinib (formerly almonertinib; HS-10296) is a novel third-generation epidermal growth factor receptor tyrosine kinase inhibitor approved in China. This double-blind phase III trial evaluated the efficacy and safety of aumolertinib compared with gefitinib as a first-line treatment for l...

Subject

Gefitinib

Medicine

Internal medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!